Volume 13, Number 7—July 2007
Research
Virulence Characteristics of Klebsiella and Clinical Manifestations of K. pneumoniae Bloodstream Infections
Table 1
Source of organism and type of infection | K1 or K2 serotype, % | Mucoid phenotype, % | Aerobactin producer, % | Mouse mortality rate, %† |
---|---|---|---|---|
Taiwan | ||||
Community-acquired | 28 (22/80) | 56 (45/80) | 54 (43/80) | 46 |
Hospital-acquired | 17 (2/12) | 25 (3/12) | 33 (4/12) | 29 |
South Africa | ||||
Community-acquired | 46 (16/35) | 60 (21/35) | 63 (22/35) | 52 |
Hospital-acquired | 16 (4/25) | 16 (4/25) | 8 (2/25) | 0 |
Rest of world | ||||
Community-acquired | 4 (1/26) | 0 (0/26) | 4 (1.26) | 0 |
Hospital-acquired | 5 (2/36) | 8 (3/36) | 8 (3/36) | 0 |
*Note the virtual absence of putative virulence factors in strains from the rest of the world, other than Taiwan and South Africa. See Results for p values.
†2 mice were tested for each available strain.
2The International Klebsiella Study Group comprises the previously named authors plus Jose Maria Casellas, Gordon Trenholme, Joseph McCormack, Sunita Mohapatra, and Lutfiye Mulazimoglu.
Page created: June 21, 2010
Page updated: June 21, 2010
Page reviewed: June 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.